Navigation Links
Addition of imidazole during binding improves purity of histidine-tagged proteins

K. Hölscher, M. Richter-Roth, and B. Felden de Neumann
GPC Biotech AG, Martinsried, Germany


The purity of histidine-tagged proteins* purified by metal chelate affinity chromatography can often be improved by optimizing the imidazole concentration in the sample and binding buffer to achieve a balance between purity and yield of the protein of interest. We determined a concentration range of imidazole that minimized the nonspecific binding of untagged proteins to Ni Sepharose™ High Performance, thereby greatly improving target protein purity. We demonstrate this approach using histidine-tagged protein kinase G ([His]6-PknG) from Mycobacterium bovis.


Introduction
The (histidine)6 tag is one of the most common tags used to facilitate the purification of recombinant proteins. However, the presence of surface-exposed histidine residues or other complex-forming amino acids can lead to nonspecific binding of untagged host cell proteins to purification media. These untagged proteins elute with the target protein and must be subsequently removed. In general, the binding affinity of these contaminants is lower than that of the tagged recombinant proteins, allowing their separation from the protein of interest by using more stringent conditions.

There are several ways to reduce the binding of contaminating proteins to Ni Sepharose media. On one hand, the amount of Ni Sepharose can be adapted to the expected amount of protein to be purified. On the other hand, imidazole can be used as a competitive agent. In this article, we demonstrate the importance of imidazole as a useful tool to enhance the purity of (His)6-PknG purified with Ni Sepharose High Performance.


Determination of the optimal imidazole concentration
To determine the optimal imidazole concentration to use during the binding of (His)6-PknG to Ni Sepharose High Performance, a cell lysate containing (His)6-PknG was loaded on a column with 10 mM imidazole in the binding buffer. After additional washing with binding buffer, (His)6-PknG was eluted using a linear gradient of up to 50% elution buffer (250 mM imidazole) within 20 column volumes (CV). By analyzing the collected fractions, it was found that most of the contaminants eluted in the range of about 40 to 70 mM imidazole (data not shown).


Improved purity
Based on this finding, 45 mM imidazole was used in the sample and binding buffer during the final purification procedure. To achieve a higher protein concentration, the protein was eluted in a two-step gradient (Fig 1). To demonstrate the advantageous effect of imidazole, an additional purification was performed under the same conditions except that imidazole was omitted from the sample and binding buffer (Fig 2). SDS-PAGE of the pooled elution fractions indicated a large improvement in purity when 45 mM imidazole was included in the sample and binding buffer (Fig 3).


Conclusion
Using a linear gradient, we determined a concentration range of imidazole that resulted in the removal of a majority of contaminating proteins, while retaining (His)6PknG. The addition of 45 mM imidazole to the sample and binding buffer resulted in much higher purity of the desired protein.

To obtain the Ni Sepharose High Performance data file (18-1174-40) visit www.amershambiosciences.com/promo_dm204



back to top
'"/>

Source:


Page: All 1 2

Related biology technology :

1. PCR Grade Deoxynucleotides Additional power to perfect your PCR experiments
2. The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays
3. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
4. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
5. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
6. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
7. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
8. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
9. The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System
10. The development of a serotonin 5-HT2C receptor-binding assay using the LEADseeker Multimodality Imaging System
11. Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... , ... January 17, 2017 , ... ... re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC ... new tools and assays, and their applicability in drug safety assessment, for the ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... and epigenetics research, recently announced a collaboration with the Heidelberg University Hospital and ... method for library preparation, following the company’s successful launch of its CATS ...
(Date:1/17/2017)... -- On January 10 at the Medtech Showcase held in ... in San Francisco , ProclaRx CEO, ... pharmaceutical leaders and public and private investors about the ... destroy biofilms.  Biofilms are a physical ... body,s immune system from eradicating chronic infections. Infections with biofilms ...
(Date:1/16/2017)... MANHASSET, N.Y. , Jan. 16, 2017   ... Kevin J. Tracey, MD , president and CEO of ... Northwell Health, completed an analysis of how the nervous ... further identify and develop bioelectronic medicine devices ... today in Nature Neuroscience . The ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported a ... over 40 granted and pending patents. ... , The Company,s IP portfolio expansion ... Device, and Method Estimating Force Applied to a Touch Surface, " ... components needed to estimate the force and pressure applied to touch surfaces ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
Breaking Biology News(10 mins):